Replies to post #86212 on Biotech Values

[biomaven0]

>>Zymo's interferon lambda deal is the best deal for a compound in phase 1

I think you are confusing biobucks and the sort of dollars issued by the Federal Reserve.

Zymo got $85 million in cash, and another $20 million license fee in 2009. The rest was all contingent on who knows what. Very rarely does even a decent fraction of biobucks ever transform to real dollars.